Roivant Sciences CEO Matthew Gline Disposes Shares for Tax Withholding
Roivant Sciences Ltd.
Subscribe to track ROIV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
{"title": "Roivant Sciences Ltd. (ROIV) Insider Filing", "description": "CEO Matthew Gline surrendered 76,171 common shares at $36.57 via net settlement to cover tax withholding obligations associated with RSU vesting.", "fields": [{"name": "Transaction Type", "value": "Tax Withholding (Code F)", "inline": true}, { ame": "Shares", "value": "76,171", "inline": true}, {"name": "Price", "value": "$36.57", "inline": true}, {"name": "Total Value", "value": "$2,785,573.47", "inline": true}, {"name": "Post-Transaction Holdings", "value": "16,583,774 shares", "inline": true}], "color": 3447003}
Comprehensive Analysis
Overview
On September 30, 2026, Matthew Gline, Chief Executive Officer and Director of Roivant Sciences Ltd. ($ROIV), disposed of 76,171 Common Shares at a price of $36.57 per share, totaling approximately $2,785,573.47. Following this transaction, Mr. Gline directly holds 16,583,774 Common Shares.
Transaction Analysis
- Nature of Transaction: The filing indicates transaction code F, reflecting a net settlement where shares were withheld by the issuer to satisfy tax withholding requirements upon the vesting of previously granted Restricted Stock Units (RSUs).
- Market Impact & Significance: Because this was a non-discretionary transaction executed strictly for tax liability purposes rather than an open-market sale, it carries Low trading significance and does not reflect a change in executive sentiment regarding the company's prospects.
- Remaining Ownership: Mr. Gline retains a substantial direct equity position of over 16.58 million shares in Roivant Sciences Ltd.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.